Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CCN6 (WISP3): a new anti-cancer therapy?

Literature DB >> 21234127

CCN6 (WISP3): a new anti-cancer therapy?

Abstract

The CCN family of matricellular proteins are dysregulated in cancers, and may strategies targeting them may represent novel approaches to treating these diseases. A recent study from Huang and colleagues (Cancer Res. 70: 3340-50, 2010) suggests that CCN6 (WISP3) is downregulated in aggressive breast cancers, and this phenomenon may result in the promotion of tumor survival. CCN6 may represent a novel therapeutic approach to breast cancer.

Entities: Disease Gene

Keywords: CCN proteins; CCN6; Cancer; WISP3

Year: 2010 PMID： 21234127 PMCID： PMC2995131 DOI： 10.1007/s12079-010-0106-y

Source DB: PubMed Journal: J Cell Commun Signal ISSN： 1873-9601 Impact factor: 5.782

14 in total

Review 1. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors: B Perbal
Journal: Mol Pathol Date: 2001-04

2. Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

Authors: Wei Huang; Maria E Gonzalez; Kathy A Toy; Mousumi Banerjee; Celina G Kleer
Journal: Cancer Res Date: 2010-04-15 Impact factor: 12.701

3. Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2.

Authors: Andrew Leask
Journal: J Cell Commun Signal Date: 2010-06-17 Impact factor: 5.782

4. Functional domains of CCN1 (Cyr61) regulate breast cancer progression.

Authors: James O'Kelly; Alice Chung; Nathan Lemp; Katya Chumakova; Dong Yin; He-Jing Wang; Jonathan Said; Dorina Gui; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
Journal: Int J Oncol Date: 2008-07 Impact factor: 5.650

5. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells.

Authors: Shr-Jeng Leu; Stephen C-T Lam; Lester F Lau
Journal: J Biol Chem Date: 2002-10-02 Impact factor: 5.157

Review 6. Functions and mechanisms of action of CCN matricellular proteins.

Authors: Chih-Chiun Chen; Lester F Lau
Journal: Int J Biochem Cell Biol Date: 2008-08-15 Impact factor: 5.085

7. Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.

Authors: Wei Huang; Yanhong Zhang; Sooryanarayana Varambally; Arul M Chinnaiyan; Mousumi Banerjee; Sofia D Merajver; Celina G Kleer
Journal: Am J Pathol Date: 2008-03-05 Impact factor: 4.307

CCN6 (WISP3): a new anti-cancer therapy?

Review 1. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

2. Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

3. Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2.

4. Functional domains of CCN1 (Cyr61) regulate breast cancer progression.

5. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells.

Review 6. Functions and mechanisms of action of CCN matricellular proteins.

7. Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.

8. Death of a tumor: targeting CCN in pancreatic cancer.

9. Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2.

Review 10. The CCN family of proteins: structure-function relationships.

1. CCN1: a novel target for pancreatic cancer.

2. Skeletal phenotype/genotype in progressive pseudorheumatoid chondrodysplasia.

3. Dysfunction of collagen synthesis and secretion in chondrocytes induced by wisp3 mutation.

4. WISP3 is highly expressed in a subset of colorectal carcinomas with a better prognosis.